Titre :
|
Persistence of use of lipid-lowering medications : A cross-national study. (1998)
|
Auteurs :
|
J. AVORN ;
R.L. BOHN ;
A. LACOUR ;
M.J. LELORIER ;
H. MOGUN ;
M. MONANE ;
J. MONETTE ;
Centre de Recherche. Hôtel-Dieu de Montréal. Université de Montréal. Montreal Quebec. CAN ;
Division of Pharmacoepidemiology and Pharmacoeconomics. Department of Medicine. Brigham and Women's Hospital. Harvard Medical School. Boston Mass. USA
|
Type de document :
|
Article
|
Dans :
|
JAMA - Journal of the american medical association (vol. 279, n° 18, 1998)
|
Pagination :
|
1458-1462
|
Langues:
|
Anglais
|
Mots-clés :
|
Statistique
;
Thérapeutique médicamenteuse
;
Thérapeutique
;
Homme
;
Canada
;
Amérique du Nord
;
Amérique
;
Etats Unis
;
Lipide
;
Métabolisme [pathologie]
|
Résumé :
|
[BDSP. Notice produite par INIST y93R0x4Z. Diffusion soumise à autorisation]. Context. - Although clinical trials have demonstrated the benefits of lipid-lowering therapy, little is known about how these drugs are prescribed or used in the general population. Objective. - To estimate predictors of persistence with therapy for lipid-lowering drug regimens in typical populations of patients in the United States and Canada. Design. - A cohort study defining all prescriptions filled for lipid-lowering drugs during 1 year, as well as patients'demographic and clinical characteristics. Setting. - New Jersey's Medicaid and Pharmacy Assistance for the Aged and Disabled programs and Quebec's provincial medical care program. Patients. - All continuously enrolled patients older than 65 years who filled 1 or more prescriptions for lipid-lowering-drugs (N=5611 in the US programs, and N=1676 drawn from a 10% sample in Quebec). Main Outcome Measures. - Proportion of days during the study year for which patients had filled prescriptions for lipid-lowering drugs ; predictors of good vs poor persistence with therapy. Results. - In both populations, patients failed to fill prescriptions for lipid-lowering drugs for about 40% of the study year. Persistence rates with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors were significantly higher than those seen with cholestyramine (64.3% vs 36.6% of days with drug available, respectively). (...)
|